| Literature DB >> 29151943 |
Jingyong Xu1,2, Xiaodong Tian1, Yiran Chen1, Yongsu Ma1, Chang Liu1, Long Tian3, Jianwei Wang3, Jianqiang Dong4, Di Cui5, Yang Wang6, Weiguang Zhang3, Yinmo Yang1.
Abstract
Mesopancreas is a controversial structure. This study aimed to explore the anatomical characteristics of the mesopancreas, define the range of the total mesopancreas excision (TMpE), and evaluate the feasibility, safety and effectivity of TMpE in the treatment of pancreatic head cancer. The clinical and pathological data of 58 consecutive patients undergoing TMpE for pancreatic head carcinoma from January 2013 to December 2015 were analyzed prospectively. The perioperative morbidity, mortality and clinical outcomes of patients undergoing TMpE were compared with the patients undergoing conventional pancreaticoduodenectomy. The mesopancreas was located in the retropancreatic area, extending from the head, neck, and uncinated process of pancreas to the aorto-caval groove, in which there were loose areolar tissue, adipose tissue, nerve plexus, lymphatic and capillaries. We observed significantly higher R0 rate (94.8% vs. 81.4%, P=0.035), more lymph nodes (16.2 vs. 11.4, P=0.000), lower total and local recurrence rate (half-year local recurrence rate 7.8% vs. 23.7%, P=0.036, one-year 18.2% vs. 39.5%, P=0.018) and longer disease-free survival (16.9 vs. 13.4 months, P=0.044) in TMpE group than in control group. In conclusion, mesopancreas is different from mesorectum because there is no fascial envelop or anatomical boundary in this area. TMpE could be safely and feasibly performed for the treatment of pancreatic head cancer to increase the R0 resection rate and improve the clinical outcomes.Entities:
Keywords: Mesopancreas; Pancreatic head cancer; Resection; Total mesopancreas excision
Year: 2017 PMID: 29151943 PMCID: PMC5687173 DOI: 10.7150/jca.21341
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Preparation and examination of the specimens. a. Sagittal dissection along the line just left of the aorta in a child specimen (view from front to back). b. The cutting lines of the sagittal dissection in a child specimen (view from left to right). Section I:from the axis of the IVC along the middle portion; Section II:from the middle of the tissues between the IVC and aorta; Section III:from the plane through the line of the CA and the SMA; Section IV:from the line of the CA and the SMA to the left edge of the aorta. c. Paraffin embedding and cutting 5 μm-thick slices. d. Representative H&E staining.
Figure 2Analysis of a normal control specimen. a. A section along the IVC (Masson III staining). The red dotted line indicated that the fascia between the pancreatic head and inferior vena cava (IVC) was loose and could be easily dissected and that the fibrous layer near the pancreas was named “posterior lateral mesopancreas”. b. A section along the aorta connecting the origins of the CA and the SMA (Masson III staining). c. A section beside the left margin of the aorta (Masson III staining). The fascia between the pancreas and the aorta was denser and contained vessels, nerves, lymphatics and several layers of fibres, which was defined as the “mesopancreatic root”. The red lines showed a relatively looser space just beneath the SMA, and between the posterior lateral mesopancreas and the retroperitoneum. d. H&E staining, and e. Masson III staining of a section from a normal adult specimen along the aorta connecting the origin of the CA and the SMA. The distance between the pancreas and the aorta was enlarged by fat tissue, and most of the structures of the mesopancreatic root distributed around the arteries.
Figure 3Analysis of specimen from unresectable pancreatic head cancer patients. a:Sagittal section of the tumour specimen dividing from the aorta connecting the origins of the CA and the SMA. b:H&E staining, the arrows indicated the front of the tumour invading along the SMA. c:Masson III staining, the dotted line showed the relatively intact fascia layers around the left renal vein (LRV). d. e. f:A section between the coeliac artery (CA) and the SMA (in the mesopancreas). d:The radiologic manifestation and the part adjusting to the specimen; e:H&E, the arrows indicated the tumour cells invading along the nerve; f:Masson III, the dotted line showed the relatively intact fascia without tumour invasion. g. h. i:A section from the lower edge of the SMA to the middle of the left renal vein. g:The radiologic manifestation adjusting to the specimen; h and i:(H&E and Masson III). The dotted line showed an intact layer of fascia with compression but without tumour invasion.
Figure 4The anatomy and concept of a total mesopancreas excision (Level I). a. b & c. Retropancreatic view via extended Kocher manoeuvre to dissect the posterior lateral mesopancreas. The red dotted line indicated the range of the TMpE. A small red or yellow circle indicated the mesopancreatic root. d, e & f. Anterior view of the range of the TMpE. The mesopancreas presented as a quadrilateral structure.
Baseline data and pathologic parameters in two groups
| CPD (n=43) | TMpE (n=58) | P value | |
|---|---|---|---|
| Age (year) | 62.98±10.51 | 63.31±9.91 | 0.871 |
| BMI (kg/m2) | 23.07±3.58 | 24.12±3.41 | 0.219 |
| Gender (M/F) | 23/20 | 40/18 | 0.112 |
| Diabetes | 9(31.0%) | 18(45.0%) | 0.241 |
| ASA score (2/3) | 24/5 | 35/5 | 0.837 |
| TBIL(mmol/L) | 148.97±163.45 | 149.09±124.20 | 0.997 |
| DBIL(mmol/L) | 109.56±129.19 | 95.74±83.39 | 0.616 |
| Album (g/L) | 38.92±4.77 | 41.18±4.55 | 0.053 |
| Size of tumor (mm) | 34.35±15.01 | 36.33±15.27 | 0.518 |
| Histological type | 0.360 | ||
| High differentiated | 3(7.0%) | 6(10.3%) | |
| Middle differentiated | 28(65.1%) | 43(74.1%) | |
| Low differentiated | 11(25.6%) | 7(12.1%) | |
| Non differentiated | 1(2.3%) | 2(3.4%) | |
| R0 resection rate | 76.7%(33/43) | 91.4%(53/58) | 0.041 |
| Number of LN resected | 11.39±2.48 | 16.24±2.75 | 0.000 |
BMI=body mass index; TBIL=total bilirubin; DBIL=direct bilirubin; LN=lymph node.
Perioperative and follow-up data in two groups
| CPD (n=43) | TMpE (n=58) | P value | |
|---|---|---|---|
| Mean operation time (min) | 397.11±112.68 | 368.60±92.48 | 0.559 |
| Mean blood loss (ml) | 532.22±319.79 | 461.38±184.49 | 0.301 |
| Cases without vessel resection | |||
| Mean operation time (min) | 380.60±113.09 | 357.39±83.11 | 0.080 |
| Mean blood loss (ml) | 515.35±299.86 | 436.67±188.73 | 0.116 |
| Total complication | 22 (51.2%) | 23 (39.7%) | 0.250 |
| Fistula | 13 (30.2%) | 15 (25.9%) | 0.628 |
| Postoperative hospital stay (day) | 28.28±18.24 | 25.66±21.76 | 0.523 |
| Adjuvant therapy | 28 (65.1%) | 43 (74.1%) | 0.327 |
| Half year total recurrence rate | 13 (34.2%) | 9 (17.6%) | 0.073 |
| Half year local recurrence rate | 9 (23.7%) | 4 (7.8%) | 0.036 |
| one year total recurrence rate | 21 (55.3%) | 15 (31.8%) | 0.054 |
| one year local recurrence rate | 15 (39.5%) | 8 (18.2%) | 0.018 |
| Median DFS (month) | 13.4 (95%CI:11.42-15.29) | 16.9 (95%CI:15.49-18.40) | 0.044 |
| Median OS (month) | 19.9 (95%CI:18.55-21.34) | 22.5 (95%CI:21.57-23.46) | 0.176 |
Figure 5Postoperative tumour-related survival curves. The postoperative tumour-related disease-free and overall survivals (DFS and OS) were both longer in TMpE group than in CPD group, with a significant difference in DFS (P=0.044).